Current post-treatment surveillance strategies for CRC anchored in serial Carcinoembryonic Antigen (CEA) monitoring and interval cross-sectional imaging with Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are codified across major society guidelines but show important limitations for early hepatic recurrence detection. The gene discussed is CEACAM5; the disease is colorectal carcinoma.